Evoke Pharma (EVOK) Competitors $5.53 -0.81 (-12.78%) Closing price 04:00 PM EasternExtended Trading$5.14 -0.39 (-7.07%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVOK vs. HYPD, ITRM, OKUR, MRSN, KLTO, PLUR, XLO, ESLA, RNXT, and SCYXShould you be buying Evoke Pharma stock or one of its competitors? The main competitors of Evoke Pharma include Hyperion DeFi (HYPD), Iterum Therapeutics (ITRM), OnKure Therapeutics (OKUR), Mersana Therapeutics (MRSN), Klotho Neurosciences (KLTO), Pluri (PLUR), Xilio Therapeutics (XLO), Estrella Immunopharma (ESLA), RenovoRx (RNXT), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceutical products" industry. Evoke Pharma vs. Its Competitors Hyperion DeFi Iterum Therapeutics OnKure Therapeutics Mersana Therapeutics Klotho Neurosciences Pluri Xilio Therapeutics Estrella Immunopharma RenovoRx SCYNEXIS Evoke Pharma (NASDAQ:EVOK) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment. Is EVOK or HYPD more profitable? Evoke Pharma has a net margin of -42.07% compared to Hyperion DeFi's net margin of -62,238.41%. Evoke Pharma's return on equity of -99.48% beat Hyperion DeFi's return on equity.Company Net Margins Return on Equity Return on Assets Evoke Pharma-42.07% -99.48% -33.58% Hyperion DeFi -62,238.41%-876.25%-181.67% Which has better earnings and valuation, EVOK or HYPD? Evoke Pharma has higher revenue and earnings than Hyperion DeFi. Evoke Pharma is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvoke Pharma$12.79M0.67-$5.35M-$2.56-2.16Hyperion DeFi$60K584.17-$49.82M-$58.40-0.11 Do insiders and institutionals believe in EVOK or HYPD? 25.8% of Hyperion DeFi shares are held by institutional investors. 2.3% of Evoke Pharma shares are held by insiders. Comparatively, 10.9% of Hyperion DeFi shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate EVOK or HYPD? Hyperion DeFi has a consensus price target of $2.00, indicating a potential downside of 67.53%. Given Hyperion DeFi's stronger consensus rating and higher probable upside, analysts plainly believe Hyperion DeFi is more favorable than Evoke Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evoke Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Hyperion DeFi 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer EVOK or HYPD? In the previous week, Evoke Pharma had 1 more articles in the media than Hyperion DeFi. MarketBeat recorded 2 mentions for Evoke Pharma and 1 mentions for Hyperion DeFi. Evoke Pharma's average media sentiment score of 0.36 beat Hyperion DeFi's score of 0.21 indicating that Evoke Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evoke Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Hyperion DeFi 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, EVOK or HYPD? Evoke Pharma has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.42, suggesting that its stock price is 142% more volatile than the S&P 500. SummaryEvoke Pharma beats Hyperion DeFi on 8 of the 15 factors compared between the two stocks. Get Evoke Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVOK vs. The Competition Export to ExcelMetricEvoke PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.62M$4.11B$5.82B$9.74BDividend YieldN/A1.24%3.84%4.09%P/E Ratio-2.1611.2531.1525.97Price / Sales0.6712.26475.57123.18Price / CashN/A6.9837.1558.38Price / Book1.974.929.116.39Net Income-$5.35M-$109.62M$3.26B$265.66M7 Day Performance8.01%4.94%2.11%1.98%1 Month Performance25.97%25.61%5.12%1.33%1 Year Performance24.83%34.49%31.25%21.15% Evoke Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOKEvoke Pharma0.4305 of 5 stars$5.53-12.8%N/A+30.5%$8.62M$12.79M-2.164Gap DownHYPDHyperion DeFi0.3011 of 5 stars$6.21-5.6%$2.00-67.8%-83.6%$37.47M$60K-0.1140Gap DownITRMIterum Therapeutics1.917 of 5 stars$0.76-8.6%$9.00+1,084.7%-42.3%$37.10MN/A-0.8910OKUROnKure Therapeutics3.2339 of 5 stars$2.73-0.4%$32.33+1,084.4%N/A$37.02MN/A-0.57N/AMRSNMersana Therapeutics4.237 of 5 stars$7.29+0.7%$56.60+676.4%-76.7%$36.13M$40.50M-0.50150KLTOKlotho NeurosciencesN/A$0.72-8.4%N/AN/A$36.12MN/A-1.60N/AEarnings ReportGap UpPLURPluri1.915 of 5 stars$4.98+10.4%$12.00+141.0%-3.8%$35.50M$330K-0.90150Negative NewsShort Interest ↑Trading HaltedXLOXilio Therapeutics2.7843 of 5 stars$0.66-2.7%$3.00+352.1%-24.7%$35.33M$6.34M-0.8770ESLAEstrella Immunopharma2.8877 of 5 stars$0.92+0.3%$16.00+1,633.5%-37.6%$34.10MN/A-3.55N/ARNXTRenovoRx2.9115 of 5 stars$0.87-5.6%$7.25+733.3%-15.7%$33.77M$40K-2.296News CoverageShort Interest ↓Analyst RevisionHigh Trading VolumeSCYXSCYNEXIS1.0345 of 5 stars$0.82+3.8%N/A-54.3%$33.12M$3.75M-2.0560News CoverageAnalyst Revision Related Companies and Tools Related Companies HYPD Alternatives ITRM Alternatives OKUR Alternatives MRSN Alternatives KLTO Alternatives PLUR Alternatives XLO Alternatives ESLA Alternatives RNXT Alternatives SCYX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVOK) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access